Porton Pharmaceutical Technology

Chongqing, China Founded: 2005 • Age: 21 yrs
Custom chemical development and manufacturing services are offered for pharmaceuticals.
Request Access

About Porton Pharmaceutical Technology

Porton Pharmaceutical Technology is a company based in Chongqing (China) founded in 2005.. Porton Pharmaceutical Technology has raised $10 million across 1 funding round from investors including Detong Capital. The company has 5,450 employees as of December 31, 2024. Porton Pharmaceutical Technology has completed 1 acquisition, including J-Star Research. Porton Pharmaceutical Technology offers products and services including Small Molecules CDMO Services, Tides CDMO Services, Biologics and Conjugates CDMO Services, and Advanced Therapy Medicinal Products. Porton Pharmaceutical Technology operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.

  • Headquarter Chongqing, China
  • Employees 5450 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Porton Pharma Solutions Ltd. Class A
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $409.62 M (USD)
    -17.5
    as on Dec 31, 2024
  • Net Profit
    $-39.42 M (USD)
    -207.83
    as on Dec 31, 2024
  • EBITDA
    $23.66 M (USD)
    -73.94
    as on Dec 31, 2024
  • Total Equity Funding
    $10 M (USD)

    in 1 rounds

  • Latest Funding Round
    $10 M (USD), Private Equity Round

    Mar 03, 2010

  • Investors
  • Employee Count
    5450

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Porton Pharmaceutical Technology

Porton Pharmaceutical Technology is a publicly listed company on the SZSE with ticker symbol 300363 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: SZSE · Ticker: 300363 . Sector: Health technology · China

Products & Services of Porton Pharmaceutical Technology

Porton Pharmaceutical Technology offers a comprehensive portfolio of products and services, including Small Molecules CDMO Services, Tides CDMO Services, Biologics and Conjugates CDMO Services, and Advanced Therapy Medicinal Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Custom development and production of small molecule APIs for partners.

Integrated CMC solutions for peptides and oligonucleotides development.

One-stop services for biologics including ADCs and conjugates.

End-to-end CRO and CDMO for viral vectors and mRNA therapies.

Funding Insights of Porton Pharmaceutical Technology

Porton Pharmaceutical Technology has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Private Equity Round round of $10 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Private Equity Round — $10.0M
  • First Round

    (03 Mar 2010)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2010 Amount Private Equity Round - Porton Pharmaceutical Technology Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Porton Pharmaceutical Technology

Porton Pharmaceutical Technology has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Detong Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Porton Pharmaceutical Technology

Porton Pharmaceutical Technology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include J-Star Research. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Custom synthesis and crystallization services for API development are provided.
1996
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Porton Pharmaceutical Technology

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Porton Pharmaceutical Technology Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Porton Pharmaceutical Technology

Porton Pharmaceutical Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical and biotechnology company
domain founded_year HQ Location
Contract development, manufacturing, and analytical services for APIs are offered.
domain founded_year HQ Location
APIs and drug products are developed and valorized in pharmaceuticals.
domain founded_year HQ Location
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
domain founded_year HQ Location
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
domain founded_year HQ Location
APIs are manufactured and custom synthesis services are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Porton Pharmaceutical Technology

Frequently Asked Questions about Porton Pharmaceutical Technology

When was Porton Pharmaceutical Technology founded?

Porton Pharmaceutical Technology was founded in 2005 and raised its 1st funding round 5 years after it was founded.

Where is Porton Pharmaceutical Technology located?

Porton Pharmaceutical Technology is headquartered in Chongqing, China.

Who is the current CEO of Porton Pharmaceutical Technology?

Nianfeng Ju is the current CEO of Porton Pharmaceutical Technology.

Is Porton Pharmaceutical Technology a funded company?

Porton Pharmaceutical Technology is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $10M, raised on Mar 03, 2010.

How many employees does Porton Pharmaceutical Technology have?

As of Dec 31, 2024, the latest employee count at Porton Pharmaceutical Technology is 5,450.

What is the annual revenue of Porton Pharmaceutical Technology?

Annual revenue of Porton Pharmaceutical Technology is $409.62M as on Dec 31, 2024.

What does Porton Pharmaceutical Technology do?

Porton Pharmaceutical Technology was founded in 2005 in Chongqing, China, where contract chemical development and manufacturing services are provided to the pharmaceutical industry. Research and development efforts focus on azides, chiral intermediates, synthons, building blocks, unnatural amino acids, heterocyclic compounds, and Grignard reagents. Manufacturing facilities have been approved by the USFDA, supporting operations in custom synthesis for global clients. Leadership is held by CEO Nianfeng Ju.

Who are the top competitors of Porton Pharmaceutical Technology?

Porton Pharmaceutical Technology's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.

What products or services does Porton Pharmaceutical Technology offer?

Porton Pharmaceutical Technology offers Small Molecules CDMO Services, Tides CDMO Services, Biologics and Conjugates CDMO Services, and Advanced Therapy Medicinal Products.

Is Porton Pharmaceutical Technology publicly traded?

Yes, Porton Pharmaceutical Technology is publicly traded on SZSE under the ticker symbol 300363.

How many acquisitions has Porton Pharmaceutical Technology made?

Porton Pharmaceutical Technology has made 1 acquisition, including J-Star Research.

Who are Porton Pharmaceutical Technology's investors?

Porton Pharmaceutical Technology has 1 investor. Key investors include Detong Capital.

What is Porton Pharmaceutical Technology's ticker symbol?

The ticker symbol of Porton Pharmaceutical Technology is 300363 on SZSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available